Inovio Pharmaceuticals Inc (INO.O) is centered around launching the global late-stage preliminary of its COVID-19 vaccine competitor one month from now, CEO Joseph Kim said in a call, with the medication engineer expecting preliminary information in the first half of next year.
In May, Inovio said it would start the study of INO-4800 in summer this year, after the vaccine competitor was observed to be protected as well as well-tolerated and produced an immune response against the new Covid in a mid-stage clinical preliminary.
The organization began creating INO-4800 last year, however fell behind rivals after the U.S. Food and Drug Administration (FDA) put a part of the U.S. study on hold for more data on the vaccine delivery gadget.
The FDA’s decision was followed by the U.S. government pulling funding for the late-stage study, refering to the fast-moving environment of vaccine development.
The global preliminary will at first spotlight on Latin America, Asia Pacific and regions in Africa, the organization said.
“We were initially focusing on Latin America and Asia Pacific, but looking at the rapidly changing vaccination rates and the virus epidemiology, we are including regions in Africa,” a company executive said during a post-earnings call on Monday.
Inovio, which has no approved drug on the market, has so far got about $85 million in joined funding from the Coalition for Epidemic Preparedness Innovations (CEPI), the Bill & Melinda Gates Foundation and the U.S. Department of Defense for the progression and manufacture of INO-4800.
Recently, Inovio extended a partnership with China’s Advaccine Biopharmaceuticals to lead the late-stage preliminary. Under the extended deal, the organizations hope to similarly share its total cost.
China’s medical product regulator has supported two Advaccine – sponsored clinical preliminaries to study the safety and ability to get resistant reactions of the combined use of the INO-4800 and a vaccine from China’s Sinovac Biotech (SVA.O), Inovio said in an official statement.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Chicago Headlines journalist was involved in the writing and production of this article.
